The SGLT-2 inhibitor 'Suglat tab 50 mg (Ipragliflozin L-Proline),' which is used as monotherapy, will no longer be available in the market in South Korea.

Three SGLT-2 monotherapies that were imported will be withdrawn from the Korean market, as Steglatro and Forxiga are set to be withdrawn.

According to the Ministry of Food and Drug Safety (MFDS) on April 10th, Astellas Korea has reported that the company will stop distributing Suglat as of August 15th due to a business decision.

Astellas explained, “We have confirmed that there are enough alternative agents available for the treatment of patients. Therefore, the likelihood of a supply shortage for the treatment o